Immunologic abnormalities in myelofibrosis with activation of the complement system.
Eighteen patients with agnogenic myeloid metaplasia with myelofibrosis were studied for clinical and laboratory evidence of immunologic dysfunction. Clinical findings included the presence of arthritis, vasculitis, and erythema nodosum. Laboratory abnormalities included the presence of circulating immune complexes, antinuclear antibodies, positive direct Coombs tests, elevated latex fixations, and a circulating lupus type anticoagulant. Total hemolytic complement was markedly depressed in four patients. Analysis of complement (C) components C1-C9 and factor B demonstrated significant reduction of only C3 and factor B. By crossed-immunoelectrophoresis, both C3 and factor B, but not C4, were cleaved, indicating that C activation was occurring predominantly via the alternative pathway. The control proteins beta 1H and C3b inactivator were decreased in three of four patients with hypocomplementemia. These data suggest that immunologic mechanisms associated with activation of the complement system play an important role in the disease process of some patients with agnogenic myeloid metaplasia with myelofibrosis.
D000368:Aged; D000936:Antigen-Antibody Complex; D002499:Centrifugation, Density Gradient; D003167:Complement Activation; D003176:Complement C3; D003178:Complement C3 Nephritic Factor; D003180:Complement C3b Inactivator Proteins; D011415:Complement Factor B; D003165:Complement System Proteins; D006801:Humans; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000150:complications* / Q000276:immunology; D011863:Radioimmunoassay
D000936:Antigen-Antibody Complex; D003176:Complement C3; D003178:Complement C3 Nephritic Factor; D003180:Complement C3b Inactivator Proteins; D003165:Complement System Proteins; D011415:Complement Factor B